HBeAg阴性慢性乙型肝炎聚乙二醇干扰素治疗后HBsAg丢失的发生

StephenW

Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-Negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study
I-Cheng Lee Sien-Sing Yang Chieh-Ju Lee Chien-Wei Su Yuan-Jen Wang Keng-Hsin Lan Han-Chieh Lin Ming-Chih Hou Cheng-Yuan Peng Yi-Hsiang Huang
The Journal of Infectious Diseases, Volume 218, Issue 7, 24 August 2018, Pages 1075–1084, https://doi.org/10.1093/infdis/jiy272
Published:
07 May 2018

Abstract
Background

The long-term incidence and factors associated with hepatitis B surface antigen (HBsAg) loss in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients receiving peginterferon is rarely reported.
Methods

From 2004 to 2016, 233 HBeAg-negative CHB patients who completed 48 weeks of peginterferon treatment from 3 medical centers in Taiwan were retrospectively enrolled.
Results

During a median follow-up of 7.4 years, 27 cases achieved HBsAg loss. The cumulative incidences of HBsAg loss and HBsAg seroconversion at 3, 5, 10 years after peginterferon treatment were 4.7%, 9.4%, 14.2%, and 3.5%, 6.4%, 12.5%, respectively, in overall patients, and 15.9%, 29.1%, 37.3%, and 13.1%, 19%, 30.6%, respectively, in patients achieving sustained off-treatment virological response (SVR). By multivariate analysis, age (<35 years; hazard ratio [HR] = 3.742, P = .007), baseline HBsAg levels (<1250 IU/mL; HR = 4.849, P = .002), HBsAg decline at week 24 (≥1 log; HR = 5.660, P = .002), and achieving SVR (HR = 8.546, P = .006) were predictors of HBsAg loss. After achieving SVR, HBsAg loss rates were higher than 30% in 5 years among patients with either younger age or lower HBsAg at baseline.
Conclusions

HBsAg loss rate continues to increase after peginterferon treatment in HBeAg-negative CHB patients with SVR. Age, baseline HBsAg levels, on-treatment HBsAg decline, and achieving SVR are factors associated with long-term HBsAg loss.
chronic hepatitis B, hepatitis B virus, peginterferon, HBsAg loss
Topic:

    follow-up hepatitis b e antigens hepatitis b surface antigens hepatitis b, chronic peginterferon

Issue Section:
Viruses

StephenW

HBeAg阴性慢性乙型肝炎聚乙二醇干扰素治疗后HBsAg丢失的发生率和预测因素：多中心，长期随访研究
I-Cheng Lee Sien-Sing Yang Chieh-Ju Lee Chien-Wei Su Yuan-Jen Wang Keng-Hsin Lan Han-Chieh Lin Ming-Chih Hou Cheng-Yuan Peng Yi-Hsiang Huang
“传染病杂志”，第218期，第7期，2018年8月24日，第1075-1084页，https：//doi.org/10.1093/infdis/jiy272
发布时间：
2018年5月7日

抽象
背景

接受聚乙二醇干扰素的乙型肝炎e抗原（HBeAg）阴性慢性乙型肝炎（CHB）患者的乙型肝炎表面抗原（HBsAg）丢失的长期发生率和相关因素很少报道。
方法

从2004年到2016年，回顾性地收集了233名HBeAg阴性的CHB患者，这些患者在台湾的3个医疗中心完成了48周的聚乙二醇干扰素治疗。
结果

在中位随访7。4年期间，27例患者出现HBsAg丢失。聚乙烯醇干扰素治疗后3年，5年，10年HBsAg消失和HBsAg血清学转换的累积发生率分别为4.7％，9.4％，14.2％和3.5％，6.4％，12.5％，15.9％，29.1在达到持续的治疗后病毒学应答（SVR）的患者中分别为％，37.3％和13.1％，19％，30.6％。通过多变量分析，年龄（<35岁;风险比[HR] = 3.742，P = .007），基线HBsAg水平（<1250 IU / mL; HR = 4.849，P = .002），HBsAg在第24周下降（ ≥1log; HR = 5.660，P = .002），实现SVR（HR = 8.546，P = .006）是HBsAg消失的预测因子。达到SVR后，在年龄较小或基线时HBsAg较低的患者中，5年内HBsAg丢失率高于30％。
结论

在使用SVR的HBeAg阴性CHB患者中，聚乙二醇干扰素治疗后HBsAg丢失率继续增加。年龄，基线HBsAg水平，治疗中HBsAg下降和实现SVR是长期HBsAg消失的相关因素。
慢性乙型肝炎，乙型肝炎病毒，聚乙二醇干扰素，HBsAg丢失
话题：

    随访乙型肝炎抗原乙型肝炎表面抗原乙型肝炎，慢性聚乙二醇干扰素

问题部分：
病毒

huajunjun

厉害